Clinical Research
Clinical Trials in Abdominal Transplantation
Clinical trials within the Divison of Abdominal Transplantation include: Tolerance Induction, EVB-induced post-transplant lymphoma, and the following Stanford-based trials for liver, kidney, intestine, pacreas, diabetes, and hepatocellular carcinoma.
This page provides an auto-populated up-to-date list of Stanford Clinical Trials in: liver, kidney, intestine, pancreas, diabetes, hepatocellular carcinoma, and pediatric transplant.
PCSK9 Inhibition After Heart Transplantation
The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: alirocumab
- biological: placebo
Eligibility
Inclusion Criteria:
- Heart Transplant recipient
Exclusion Criteria:
- impaired liver function
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-724-2883
I'm interested